Antibiotic Resistance Market to $12.72B by 2031 at 5.4% CAGR Bolsters AstraZeneca Prospects
The antibiotic resistance market is forecast to climb from USD 9.78 billion in 2026 to USD 12.72 billion by 2031, driven by resistant infections and diagnostics advances. AstraZeneca stock was one of the FTSE 100’s top fallers at the April 28 open on sector profit concerns and oil volatility.
1. Antibiotic Resistance Market Growth Forecast
The global antibiotic resistance market is expected to rise from USD 9.78 billion in 2026 to USD 12.72 billion by 2031, reflecting a 5.4% CAGR. Growth is underpinned by the surge in multidrug-resistant infections and advances in rapid diagnostic tools and novel antimicrobial therapies, with North America leading and Asia-Pacific the fastest expanding.
2. AstraZeneca Share Performance at FTSE Open
On April 28, AstraZeneca shares ranked among the FTSE 100’s top decliners as the index opened down 11 points. Broader sector profit worries, oil price swings and weak results from peers contributed to pressure on drugmaker stocks, prompting the drop in AstraZeneca’s early session performance.